The blockbuster weight loss drug Wegovy has a new rival. Today, the US Food and Drug Administration approved a new drug for weight management called Zepbound, made by American pharmaceutical company Eli Lilly.
The weekly injectable drug is meant for adults who are overweight or obese and have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol. The active ingredient in Zepbound, tirzepatide, is already approved under the brand name Mounjaro to help improve blood sugar in adults with type 2 diabetes and is widely prescribed off-label for weight loss.
Zepbound and Mounjaro are similar to the better-known Wegovy and Ozempic, which are both
→ Continue reading at Wired - Science